

EXEMPLARS AND INNOVATIONS IN DIAGNOSTICS









EXEMPLARS AND INNOVATIONS IN DIAGNOSTICS

EXEMPLARS OVERVIEW

Exemplars in Global Health (EGH) brings together experts, funders, and partners around the world with the mission of identifying positive global health outliers, analyzing what makes countries successful, and disseminating core lessons so they can be adapted in comparable settings. EGH aims to help country-level decision makers, global partners, and funders make strategic decisions, allocate resources, and craft evidence-based policies. EGH is based at Gates Ventures, the private office of Bill gates, and collaborates with the Bill & Melinda Gates Foundation.

INNOVATION SELECTION PROCESS

When considering which innovations to study, we focus on four key requirements:

- 1. Be first-in-class technology
- 2. Have no previous diagnostics (i.e., novel technology)
- 3. Been tested on nonconventional specimen types
- 4. Be people oriented

COUNTRY SELECTION PROCESS

To select Exemplar countries, we are using a unique country selection process for each case study based on the topic or disease being studied. For the first Exemplar case study, we used a four-step approach outlined in Figure 2 and vetted the final top candidates with experts and the TAG before selecting the Exemplar country.

EXEMPLAR COUNTRY AND INNOVATION CASE STUDIES

The first case studies focused on: (1) the innovation of rapid diagnostic test (RDT) for human African trypanosomiasis (HAT), and (2) studying the positive outlier in HIV testing where Zimbabwe emerged as the Exemplar country. The second case studies are exploring: (1) HIV self-tests as an innovation, and (2) the Exemplar country in diagnostics during antenatal care visit. Future case studies will be selected based on information need from stakeholders.

TOPIC OVERVIEW

47% of the global population have little or no access to appropriate diagnostic services. Despite being fundamental to delivering quality care, the role of diagnostics in health care delivery has been overlooked, with substantial burden carried by low-and middle-income countries (LMICs) and low-income groups in high-income countries. Improving access to diagnostics is key to achieving health equity and Universal Health Coverage (UHC).

This project has two aims:

- 1. Identify **innovations** (e.g., products or diagnostic tools) that have high potential to close the diagnostics gap and ranges from R&D to global policy.
- 2. Identify **Exemplars** (e.g., countries that successfully implemented programs in screening, testing, and linkage to care within the cascade of care). This spans from global policy to clinical and public health impact on the diagnostics value chain (Figure 1).

This project will be conducted in "sprint" format case studies (each with a \sim 3-4-month study duration). Exemplar countries and innovations are chosen based on the information need identified by stakeholders and partners.

Findings will describe key lessons from each innovation or Exemplar country. This work will generate evidence to support innovators, implementers, and decision-makers in designing strategies (such as the development of new technologies, the formation and prioritization of new policies, and resource mobilization and optimization) to close the diagnostics gap within the cascade of care for infectious diseases and non-communicable diseases (NCD).

Technical Advisory Group

Research for every Exemplars in Global Health topic is guided by a Technical Advisory Group (TAG), consisting of a diverse range of topic-specific experts. The Diagnostics TAG consists of:

Dr. Marguerite Loembe (Senior Science Manager, African Society for Laboratory Medicine (ASLM) and TAG chair); Prof. Kenneth Fleming (Chair of Lancet Commission on Diagnostics); Dr. Pascale Ondoa (Director of Science and New Initiatives, ASLM); Dr. Kayla Laserson (Deputy Director of Infectious Diseases and Vaccine Delivery, Bill and Melinda Gates Foundation, India); Dr. Yogan Pillay (Director of HIV and TB delivery, Bill and Melinda Gates Foundation); Dr. Kamini Walia (Senior Scientist, India Council of Medical Research); Dr. Emma Hannay (Chief Access Officer, FIND); Dr. Trevor Peter (Head of Diagnostics, CHAI); Prof. Andrew Vallely and Dr. Philip Cunningham (Kirby Institute at the University of New South Wales (UNSW) in Sydney)

FIG. 1 | INNOVATION AND EXEMPLARS ACROSS THE DIAGNOSTICS VALUE CHAIN

INNOVATION Global Country Public Regulatory Clinical R&D Evaluation Policy Adoption Health Scale-up Approval **Impact** (eg: WHO) & Policy Impact






EXEMPLARS AND INNOVATIONS IN DIAGNOSTICS




Learn more: www.exemplars.health
 Follow us: Exemplars in Global Healt

Follow us: Exemplars in Global Health
Follow us: @exemplarshealth

FIG. 2 | APPROACH TO SELECT HIV DIAGNOSTICS EXEMPLAR



FOUR STEP PROCESS TO NARROW COUNTRIES



Research Partners

This project was designed by a team consisting of researchers from the EGH program, the Research Institute of the McGill University Health Centre and FIND, a non-profit diagnostics partnership.





METHODOLOGY

When selecting and studying the Innovations and Exemplars, we are using a mixed methods approach to assess characteristics of each innovation that enable its potential to accelerate progress in diagnosis and learn how Exemplar countries achieved successful diagnostics service delivery by testing everyone who needed to be tested (Figures 3 and 4).

EMERGING FINDINGS

Rapid diagnostic test (RDT) for human African trypanosomiasis (HAT)

- HAT RDTs improved access to HAT screening at lower levels of care and hard-to-reach populations
- Success was enabled by the World Health Organization's leadership and commitment to accelerate the control and elimination of HAT in combination with strong global funding sources
- Early engagement with different governmental and non-governmental country stakeholders to complete development and obtain regulatory approvals contributed to the success of this HAT RDTs

HIV testing in Zimbabwe

Success achieved in HIV testing was enabled by:

- High knowledge of HIV and where to go get tested among residents
- Increased community-based testing and anonymous HIV testing that reduced stigma
- Government and civil society awareness campaigns
- Testing of key population groups such as pregnant women
- · Effective use of resources

FIG. 3 | CONCEPTUAL FRAMEWORK (INNOVATIONS)

CONTEXT AND ENABLERS INTERMEDIATE DRIVERS OUTCOME R&D **ACCESS** Target product profile Affordability First in class IVD Ease of use Adjustment to population needs Deployability Scalability **POLICY LEVERS GLOBAL AND/OR COUNTRY** Governance **UPTAKE OF THE INNOVATION** Policy profiles, roadmaps, etc. Financing FOR IMPLEMENTATION OR Funding & allocation of resources **COUNTRY EVALUATION** ASSESSMENT. Early partnership with Ministry Engagement with private sector of Health and governments **Engagement with ROLE OF DIAGNOSTICS** communities, civil society Establish diagnosis and other stakeholders Case management Guide therapy

DISEASE CHARACTERISTICS • Chronic vs. acute, severity distribution/latency, co-morbidities, symptom presentation

FIG. 4 | CONCEPTUAL FRAMEWORK (EXEMPLARS)

OUTCOME CONTEXT AND ENABLERS INTERMEDIATE DRIVERS **POLICY LEVERS DIAGNOSTICS CAPACITY** Facility/System readiness Leadership & Governance Financing Adjustment to population needs Monitoring and Evaluation Digital technology for Diagnostics **SERVICE DELIVERY TECHNOLOGY/MARKET PUSHES** Models of care Testing modality MET NEED FOR TESTING Quality care Device capabilities Access and availability Macroeconomics forces **ROLE OF DIAGNOSTICS** INTENT TO GET TESTED Establish diagnosis Attitude Prognosticate Knowledge & dx literacy Guide therapy & Monitor progress Acceptability of available testing Establish population-level diagnosis

DISEASE CHARACTERISTICS • Burden of the disease, severity distribution/latency, disease progression, co-morbidities...